SMS Pharmaceuticals gets license to Pfizer Covid‐19 drug nirmatrelvir
SMS Pharmaceuticals has secured a non‐exclusive license via the Medicines Patent Pool (MPP) for manufacturing nirmatrelvir, an oral antiviral Covid‐19 drug developed by Pfizer, to increase wider access to treatment in 95 low‐ and middle‐ income countries. Previously, Pfizer had announced that the clinical trial of PAXLOVID (nirmatrelvir tablets and ritonavir tablets) demonstrated significant reduction […]